ICiAF

ICiAF:

Leading product BIC-020 is in the late preclinical stage, and BIC-021 is in early preclinical stage. Both BIC-020 and BIC-021 combine different tumor antigen specificity with PD1/PDL1 and PD1/PDL2 signaling blockade, which minimizes the adverse effects due to systemic inhibition of PD1 signaling while enhances the efficacy by tumor targeted enrichment. The leading product BIC-020 has similar PK profile as mAb and significant inhibition of tumor growth with tumor target preference in rodent studies.

  • First-in-class bispecific antibody targeting PD-L1, PD-L2 and EGFR
  • High production yield in stable CHO expression system
  • High homogeneity and stability
  • Enhanced efficacy and safety by synergize the PD1/PD-L1 & PD1/PD-L2 signaling inhibition with specific EGFR+ tumor targeting
  • New solution for tumors with moderate to low expression of PD-L1
  • Improved therapeutic index for drug combination strategies
  • Broad market prospects: solves the problem of low response rate (<30%) of existing immune checkpoint inhibitors and has a wide range of indications of EGFR+ malignancy
Scroll to Top